New Jersey Judge Rules $450M Stem Cell Bond Proposal Must Remain On Nov. 6 Ballot
Main Category: Stem Cell ResearchAlso Included In: Litigation / Medical Malpractice; Women's Health / Gynecology
Article Date: 27 Sep 2007 - 2:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
| Article Opinions: | 2 posts |
According to a ruling that Mercer County, N.J., Superior Court Judge Neil Shuster issued on Monday, a referendum that asks voters to approve borrowing $450 million over 10 years to fund stem cell research in the state must remain on the Nov. 6 ballot, the New York Times reports (Peters, New York Times, 9/25).
In July, New Jersey Gov. Jon Corzine (D) signed a bill authorizing the referendum. The state Assembly in June voted 50-27 and the Senate 31-3 to approve the legislation. If approved by voters, the funds would be used to award grants to institutions -- including colleges, universities, and state and local government agencies -- that conduct research on both adult and human embryonic stem cells, and umbilical cord blood, according to state Rep. Neil Cohen (D). Borrowing for stem cell research could increase the state's debt by as much as $37 million annually, according to a nonpartisan legislative analysis.
The antiabortion group Legal Center for the Defense of Life earlier this month filed a lawsuit on behalf of New Jersey Right to Life and 15 New Jersey residents in Trenton, N.J., Superior Court, alleging that the ballot question is deceptive because it does not explain that the borrowed funds would pay for human cloning or that the debt could be repaid with property taxes. The suit seeks to stop printing of the ballot and to bar the question from going to voters (Kaiser Daily Women's Health Policy Report, 9/20).
Ruling
Shuster ruled that the ballot proposal appears "fair, balanced and neutral" and rejected the argument that it is misleading to voters, the Newark Star-Ledger reports. He also rejected the groups' request to delay the printing of ballots for the election, allowing county clerks to begin printing the ballots Monday.
Absentee ballots are scheduled to be delivered to military personnel and others beginning on Friday, the Star-Ledger reports. "The public has an interest in voting on Election Day, ... [a]nd by enjoining the printing of ballots, the court would put at risk the ability of our military and others to vote" (McNichol, Newark Star-Ledger, 9/25).
Shuster also said, "The issue for the court is not political, philosophical, moral or religious," adding that his decision simply was based on whether the court should remove a referendum that had been approved by the Legislature. According to the Times, Shuster "left open the possibility" that antiabortion groups could appeal or challenge the results if the proposal is approved.
Bertram Goltz, an attorney for the plaintiffs, said after the ruling that he had not decided whether to appeal the ruling (New York Times, 9/25). Marie Tasy, executive director of NJRTL, criticized the ruling, saying, "The franchise of voting has been tampered with" (Hester, AP/Houston Chronicle, 9/24). Tasy said, "This is a matter that affects the future of humanity," adding, "It's much too important a matter to be ignored." Cohen applauded the decision, saying, "As we predicted, this lawsuit was completely without merit." He added, "The people who are seeking to block progress with ideology should get out of the way" (Newark Star-Ledger, 9/25).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our stem cell research section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/83641.php>
APA
http://www.medicalnewstoday.com/releases/83641.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (2)
Where Is The Embryonic Stem Cell Research?
posted by Bob on 27 Sep 2007 at 1:30 pmWhere is the embryonic stem cell research promised the New Jersey voters?
So far the state has basically been funding the already existing adult stem cell industry. What was supposed to prioritize embryonic stem cell research has turned into a bonanza for adult stem cell research. Out of the 33 grants awarded in the last 2 review periods, 28 have gone to adult stem cell research. It may be time for embryonic stem cell supporters to ask for accountability.
Understanding Stem Cells
posted by Gregory D. Pawelski on 28 Sep 2007 at 6:09 pmThere was a very interesting article on embryonic stem cells and cancer reported in the May 16, 2007 issue of Molecular Biology of the Cell. British scientists have made a breakthrough in understanding how cancers spread, which could lead to new methods of fighting the disease.
The University of Manchester study used embryonic stem cells to investigate how some tumors are able to migrate to other parts of the body, thus making cancer treatments more difficult.
Christopher M. Ward, the lead researcher, and colleagues studied a crucial change what makes cancer cells able to start moving and spread into other tissues. Known as the epithelial-mesenchymal transition, this crucial change was observed in the early embryo, theorizing that embryonic stem cells might undergo a similar process.
They have shown embryonic stem cells spontaneously change in a manner that is remarkably similar to the epithelial-mesenchymal transition. They lose the proteins that cells use to bind to each other and have other protein alterations that are characteristic of spreading cancer cells.
Studying such cells, researchers have identified a novel component of the transition process and expect to identify other factors involved in cancer cell spread, hopefully leading to new cancer therapies.
http://www.molbiolcell.org/cgi/repri...urcetype=HWCIT
Abstract
http://www.molbiolcell.org/cgi/conte...urcetype=HWCIT
To evade chemotherapy, some cancer cells mimic stem cells. Research has shown that anti-cancer treatments might actually expand the small population of cancer stem cells believed to drive the disease. Experiments suggest that some treatments could be producing more cancer stem cells that then are capable of metastasizing, because these cells are trying to find a way to survive the therapy.
This may help explain why the expression of stem cell markers has been associated with resistance to chemotherapy and radiation treatments and poor outcome for patients with cancers. That tells us that understanding how to target these markers and these cells could prove useful in treating cancer. The cancer stem cell markers contribute to stem cells' defining ability to renew themselves and differentiate into different cell types. These same molecules are found in embryonic stem cells.
http://www.aacr.org/home/public--media/news-releases.aspx?d=822
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




